Daniel Varón
A5069737780- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Neurological Disease Mechanisms and Treatments
- Bioinformatics and Genomic Networks
- Brain Tumor Detection and Classification
- Advanced Neuroimaging Techniques and Applications
- Memory and Neural Mechanisms
- Genetic Associations and Epidemiology
- Metabolomics and Mass Spectrometry Studies
- Acute Ischemic Stroke Management
- Health, Environment, Cognitive Aging
- Machine Learning in Healthcare
- Vascular Malformations Diagnosis and Treatment
- Nutrition, Genetics, and Disease
- Intracerebral and Subarachnoid Hemorrhage Research
- Trace Elements in Health
- Diet and metabolism studies
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Mental Health Research Topics
- Prion Diseases and Protein Misfolding
- Frailty in Older Adults
- Amyotrophic Lateral Sclerosis Research
- Neural dynamics and brain function
- Inflammation biomarkers and pathways
University of California, San Francisco
2024
San Francisco VA Medical Center
2024
Johns Hopkins University
2022-2023
Institut Català d'Oncologia
2023
Cohort (United Kingdom)
2023
Alzheimer’s Disease Neuroimaging Initiative
2023
University of Pittsburgh Medical Center
2019
Hospital Universitario del Valle ESE
2016
University of Pittsburgh
2008-2015
Mount Sinai Medical Center
2010-2014
Abstract Alzheimer’s Disease (AD) is a progressive neurodegenerative disease where biomarkers for based on pathophysiology may be able to provide objective measures diagnosis and staging. Neuroimaging scans acquired from MRI metabolism images obtained by FDG-PET in-vivo measurements of structure function (glucose metabolism) in living brain. It hypothesized that combining multiple different image modalities providing complementary information could help improve early AD. In this paper, we...
To investigate the vascular contribution to longitudinal changes in Alzheimer disease (AD) biomarkers.The Alzheimer's Disease Neuroimaging Initiative is a clinic based, study with CSF, PET, and MRI biomarkers repeatedly measured participants normal cognition (NC), mild cognitive impairment (MCI), AD. Participants severe cerebrovascular risks were excluded. Cardiovascular risk scores white matter hyperintensities (WMHs) treated as surrogate markers for burden. Generalized estimating equations...
<h3>Objective:</h3> To assess the frequency and phenotype of hexanucleotide repeat expansions in <i>C9ORF72</i> a large cohort patients Dutch descent with familial (fALS) sporadic (sALS) amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), primary (PLS). <h3>Methods:</h3> Included were 78 fALS, 1,422 sALS, 246 PMA, 110 PLS, 768 control subjects. Repeat determined by primed PCR. Familial aggregation dementia Parkinson disease (PD) was examined among ALS who carried...
Accurate diagnosis of mild cognitive impairment (MCI) before conversion to Alzheimer's disease (AD) is invaluable for patient treatment. Many works showed that MCI and AD affect functional structural connections between brain regions as well the shape cortical regions. However, 'shape connections' are rarely investigated -e.g., how morphological attributes such thickness sulcal depth a specific region change in relation other To fill this gap, we unprecedentedly design multiplexes late...
Abstract Background The Apolipoprotein E ε4 allele (i.e. ApoE4) is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD). TREM2 Triggering receptor expressed on myeloid cells 2) a microglial transmembrane protein brain that plays central role in microglia activation response to AD pathologies. Whether higher TREM2-related activity modulates develop clinical an open question. Thus, aim of current study was assess whether sTREM2 attenuates effects ApoE4-effects future...
Abstract Objective To evaluate the contributions of amyloid‐positive (Am+) and medial temporal atrophy–positive (MTA+) scans to diagnostic classification prodromal probable Alzheimer's disease (AD). Methods 18 F‐flutemetamol‐labeled amyloid positron emission tomography (PET) magnetic resonance imaging (MRI) were used classify 10 young normal, 15 elderly 20 amnestic mild cognitive impairment (aMCI), 27 AD subjects. MTA+ status was determined using a cut point derived from previous study, Am+...
Neuroimaging genetics is an emerging field that aims to identify the associations between genetic variants (e.g., single nucleotide polymorphisms (SNPs)) and quantitative traits (QTs) such as brain imaging phenotypes. In recent studies, in order detect complex multi-SNP-multi-QT associations, bi-multivariate techniques various structured sparse canonical correlation analysis (SCCA) algorithms have been proposed used studies. However, markers QTs identified by existing methods may not be all...
Polygenic effects have been proposed to account for some disease phenotypes; these are calculated as a polygenic risk score (PRS). This is correlated with Alzheimer's (AD)-related phenotypes, such biomarker abnormalities and brain atrophy, associated conversion from mild cognitive impairment (MCI) AD. However, the AD PRS has examined mainly in Europeans, owing differences genetic structure lifestyle, it unclear whether same relationships between AD-related phenotypes exist non-European...
Background: Psychotic symptoms in Alzheimer disease (AD + P) identify a heritable phenotype associated with greater cognitive impairment. Knowing when the course of AD P subjects diverges from that without psychosis would enhance understanding how genetic variation results and its burden. This study seeks to determine whether degree impairment decline early predicts subsequent onset.Methods: 361 possible or probable mild (MCI) were evaluated every 6 months until onset.Results: Severity...
<h3>Background:</h3> The goal of this study was to identify a clinical biomarker signature brain amyloidosis in the Alzheimer9s Disease Neuroimaging Initiative 1 (ADNI1) mild cognitive impairment (MCI) cohort. <h3>Methods:</h3> We developed multimodal classifier for predicting using cognitive, imaging, and peripheral blood protein ADNI1 MCI data. used CSF β-amyloid 1–42 (Aβ<sub>42</sub>) ≤192 pg/mL as proxy measure Pittsburgh compound B (PiB)-PET standard uptake value ratio ≥1.5. trained our...
Alzheimer's disease, the most common cause of dementia, causes a progressive and irreversible deterioration cognition that can sometimes be difficult to diagnose, leading suboptimal patient care.
Abstract Background/Aims To investigate the clinical features and rates of progression conditions that are not considered to be normal, but do fulfill criteria for mild cognitive impairment (MCI). Methods We longitudinally evaluated 269 elderly subjects who did meet formal MCI at baseline had: (1) a history suggesting without neuropsychological deficits (PreMCI‐Clinical); or (2) on one more memory measures in conjunction with negative examination (amnestic PreMCI‐NP) were normal both...
To investigate predictors of missing data in a longitudinal study Alzheimer disease (AD).The Alzheimer's Disease Neuroimaging Initiative (ADNI) is clinic-based, multicenter, with blood, CSF, PET, and MRI scans repeatedly measured 229 participants normal cognition (NC), 397 mild cognitive impairment (MCI), 193 AD during 2005-2007. We used univariate multivariable logistic regression models to examine the associations between baseline demographic/clinical features loss biomarker follow-ups...
Background: New research criteria for diagnosing Alzheimer's disease (AD) in the mild cognitive impairment stage (MCI-AD) incorporate biomarkers to assign a level of certainty diagnosis. Structural MRI is widely available but greatly under-utilized assessing atrophy structures affected early AD, such as hippocampus (HP), because quantification HP volumes (HP-v) requires special expertise, and normative values have not been established. Methods: Elderly subjects (n =273) from Florida ADRC...
Objective This study aims to determine the clinical utility of visual ratings and volumetric measurements medial temporal atrophy among subjects from Alzheimer's Disease Neurorimaging Initiative (ADNI) cohort. Methods A sample 189 ADNI, Phase 1 (ADNI-1), was chosen as follows: 49 cognitively normal (CN), 89 with mild cognitive impairment (MCI), 50 disease (AD). Structural MRI images were downloaded ADNI website, a rating system (VRS) used obtain semi-quantitative hippocampus (HPC) entorhinal...
In Alzheimer's disease, neurodegenerative atrophy progresses from the entorhinal cortex (ERC) to hippocampus (HP), limbic system and neocortex. The significance of very mild ERC HP on MRI scans among elderly subjects is unknown.A validated visual rating coronal was used identify no or (HP(0); ERC(0)), minimal (HP(ma); ERC(ma)), 414 participants. Subjects fell into following groups: (1) ERC(0)/HP(0), (2) ERC(ma)/HP(0), (3) ERC(0)/HP(ma), (4) ERC(ma)/HP(ma). volume independently measured using...
It is increasingly recognized that Alzheimer's disease (AD) exists before dementia present and shifts in amyloid beta occur long clinical symptoms can be detected. Early detection of these molecular changes a key aspect for the success interventions aimed at slowing down rates cognitive decline. Recent evidence indicates two established methods measuring amyloid, decrease cerebrospinal fluid (CSF) β
Abstract Adult neurogenesis occurs in the dentate gyrus of hippocampus during adulthood and contributes to sustaining hippocampal formation. To investigate whether neurogenesis-related pathways are associated with volume, we performed gene-set enrichment analysis using summary statistics from a large-scale genome-wide association study (N = 13,163) volume Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium two year changes baseline cognitively normal individuals...
Identifying prediagnostic neurodegenerative disease is a critical issue in research, and Alzheimer's (AD) particular, to identify populations suitable for preventive early disease-modifying trials. Evidence from genetic other studies suggests the neurodegeneration of measured by brain atrophy starts many years before diagnosis, but it unclear whether these changes can be used reliably detect sporadic disease.
Abstract The introduction of mild cognitive impairment (MCI) as a diagnostic category adds to the challenges diagnosing Alzheimer’s Disease (AD). No single marker has been proven accurately categorize patients into their respective groups. Thus, previous studies have attempted develop fused predictors AD and MCI. These two main limitations. Most do not simultaneously consider all categories provide suboptimal representations using same set modalities for prediction classes. In this work, we...
The objective of this study was to investigate the incidence acute flaccid paralysis in pediatric population Honduras over an 11-year period, determine what percentage Guillain-Barré syndrome, and identify epidemiologic features syndrome. There were 546 childhood cases seen between January 1989 December 1999 at Hospital Escuela Materno-Infantil Tegucigalpa, Honduras. Of these with paralysis, 394 (72.2%) diagnosed Our syndrome Honduran (1.37/100,000 per year) is higher than that shown other...
The purpose of Nonviolent or Empathic Communication Training is to facilitate the flow information necessary for people work cooperatively and resolve differences effectively. Such training widely used in medical communities where communication with patients cooperation between team members are critical importance effectiveness treatment. skills particular health care providers dealing having chronic diseases such as haemophilia. In addition difficulties inherent chronicity disease, HIV...